Salem Riad, Vouche Michael, Baker Talia, Herrero Jose Ignacio, Caicedo Juan Carlos, Fryer Jonathan, Hickey Ryan, Habib Ali, Abecassis Michael, Koller Felicitas, Vogelzang Robert, Desai Kush, Thornburg Bartley, Hohlastos Elias, Resnick Scott, Lewandowski Robert J, Sato Kent, Ryu Robert K, Ganger Daniel, Kulik Laura
1Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago IL. 2Department of Transplantation, Northwestern University, Chicago, IL. 3Liver Unit, Clinica Universidad de Navarra, Pamplona, Navarra, Spain. 4Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd), Barcelona, Spain. 5Division of Hepatology, Department of Medicine, Northwestern University, Chicago, IL.
Transplantation. 2015 Nov;99(11):2347-55. doi: 10.1097/TP.0000000000000729.
Chronic, obliterative portal vein (PV) thrombosis (PVT) represents a relative contraindication to liver transplantation (LT) in some centers. When PV thromboembolectomy is not feasible, alternative techniques (portacaval hemitransposition, portal arterialization, multivisceral transplantation) are associated with suboptimal outcomes. In cases where a chronically thrombosed PV has become obliterated, we developed PV recanalization (PVR)-transjugular intrahepatic portosystemic shunt (TIPS) to potentiate LT. We evaluated the impact of PVR-TIPS on liver function, transplant eligibility, and long-term outcomes after LT.
Forty-four patients with chronic obliterative main PVT were identified during our institutional LT selection committee. After joint imaging review by transplant surgery/radiology, these patients underwent PVR-TIPS to potentiate transplant eligibility. Patients were followed by hepatology/transplant until LT, and ultimately in posttransplant clinic. The TIPS venography and serial ultrasound/MRI were used subsequently to document PV patency.
The main PV (MPV) was completely thrombosed in 17 of 44 (39%) patients; near complete (>95%) occlusion was noted in 27 of 44 (61%) patients. Direct transhepatic and transsplenic punctures were required in 11 of 43 (26%) and 3 of 43 (7%) cases, respectively. Technical success was 43 of 44 (98%) cases. At PVR-TIPS completion, persistence of MPV thrombus was noted in 33 of 43 (77%) cases. One-month TIPS venography demonstrated complete resolution of MPV thrombosis in 22 of 29 (76%) without anticoagulation. Thirty-six patients were listed for transplantation; 18 (50%) have been transplanted. Eighty-nine percent MPV patency rate and 82% survival were achieved at 5 years.
The PVR-TIPS may be considered for patients with obliterative PVT who are otherwise appropriate candidates for LT. The high rate of MPV patency post-TIPS placement suggests flow reestablishment as the dominant mechanism of thrombus resolution.
在一些中心,慢性闭塞性门静脉(PV)血栓形成(PVT)是肝移植(LT)的相对禁忌证。当PV血栓切除术不可行时,替代技术(门腔半转位、门静脉动脉化、多脏器移植)的效果并不理想。对于慢性血栓形成导致PV闭塞的病例,我们开展了门静脉再通(PVR)-经颈静脉肝内门体分流术(TIPS)以促进LT。我们评估了PVR-TIPS对肝功能、移植适应证以及LT后长期结局的影响。
在我们机构的LT选拔委员会中确定了44例慢性闭塞性主PVT患者。经移植外科/放射科联合影像评估后,这些患者接受PVR-TIPS以提高移植适应证。患者在肝科/移植科接受随访直至LT,最终在移植后门诊随访。随后使用TIPS静脉造影和系列超声/MRI记录PV通畅情况。
44例患者中有17例(39%)主门静脉(MPV)完全血栓形成;44例中有27例(61%)出现近乎完全(>95%)闭塞。43例中分别有11例(26%)和3例(7%)需要直接经肝穿刺和经脾穿刺。44例中有43例(98%)技术成功。在完成PVR-TIPS时,43例中有33例(77%)发现MPV血栓持续存在。1个月时的TIPS静脉造影显示,29例中有22例(76%)在未抗凝的情况下MPV血栓完全溶解。36例患者被列入移植名单;18例(50%)已接受移植。5年时MPV通畅率为89%,生存率为82%。
对于闭塞性PVT且其他方面适合LT的患者,可考虑采用PVR-TIPS。TIPS置入后门静脉通畅率高表明血流重建是血栓溶解的主要机制。